These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11572178)

  • 1. [Misleading advertisement of Adalat Oros].
    Verheugt FW
    Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1751-2. PubMed ID: 11572178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Misleading advertisement of Adalat Oros].
    Cleophas TJ
    Ned Tijdschr Geneeskd; 2002 Jan; 146(2):88-9. PubMed ID: 11820065
    [No Abstract]   [Full Text] [Related]  

  • 3. [Misleading advertisement of Adalat Oros].
    Moesker HL
    Ned Tijdschr Geneeskd; 2002 Jan; 146(2):89. PubMed ID: 11820066
    [No Abstract]   [Full Text] [Related]  

  • 4. [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
    Hoogenberg K; van der Tuin J
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2099-100. PubMed ID: 12448967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of nifedipine in the treatment of hypertension.
    Pontremoli R; Leoncini G; Parodi A
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):43-50. PubMed ID: 15723574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes.
    Heagerty AM
    Int J Clin Pract; 2005 Sep; 59(9):1112-9. PubMed ID: 16115193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
    Hildebrandt PR; Tuxen CD; Kjeldsen SE; Lund-Johansen P; Hansson L
    Ugeskr Laeger; 2001 Dec; 164(1):18-21. PubMed ID: 11810791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living up to 100 years of Bayer Healthcare cardiovascular protection - Bayer Healthcare Cardiovascular : 20 years of participation in the South African cardiovascular community.
    Cardiovasc J Afr; 2009; 20(1):91-4. PubMed ID: 19287826
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The ACCOMPLISH trial: are results really unexpected?].
    Waeber B; Feihl F
    Rev Med Suisse; 2009 Jan; 5(185):25-8. PubMed ID: 19216321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treating hypertension is more important than the choice of agent; results from the largest clinical trial until now].
    de Leeuw PW; Birkenhäger WH
    Ned Tijdschr Geneeskd; 2003 Apr; 147(15):685-9. PubMed ID: 12722529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Jan; 14(2):5-7. PubMed ID: 12776699
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
    Sierra C; Coca A
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1055-62. PubMed ID: 18793108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.